As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
The CliniMACS® CD34 Reagent System is an FDA-approved method to deplete T cells as an effective means of GVHD prophylaxis in patients with AML undergoing allogeneic stem cell transplantation in 1st complete remission.
See the data and learn about the CliniMACS CD34 Reagent System.
Humanitarian Device
Authorized by U.S. Federal Law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this use has not been demonstrated.
Indications for Use
The CliniMACS® CD34 Reagent System is indicated for processing hematopoietic progenitor cells collected by apheresis (HPC, Apheresis) from an allogeneic, HLA-identical, sibling donor to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional graft versus host disease (GVHD) prophylaxis in patients with acute myeloid leukemia (AML) in first morphologic complete remission.
Contraindications
Do not use CD34+ cells prepared with CliniMACS CD34 Reagent System in patients with known hypersensitivity to murine (mouse) proteins or iron dextran.
Rx only
Miltenyi Biotec Inc.
phone: +1 800 FOR MACS
fax: + 1 530 745 2806
macs@miltenyibiotec.com
Copyright © 2020 Miltenyi Biotec and/or its affiliates. All rights reserved.
